---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-099424"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:44:50.182816+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics FY2025 net loss narrows to $99.5M; cash $106.4M; IND cleared for PRT12396

## Summary
- Net loss of $99.5M ($1.29/share) improved from $127.2M ($1.68/share) in 2024.
- Cash, equivalents and marketable securities $106.4M as of Dec 31, 2025; runway into Q2 2027.
- FDA cleared IND for PRT12396 (mutant-selective JAK2V617F inhibitor); Phase 1 start expected Q2 2026.
- KAT6A degrader PRT13722 IND filing planned mid-2026; Phase 1 initiation in H2 2026.
- Exclusive option agreement with Incyte for JAK2 program (Nov 2025); DAC collaboration with AbCellera expanded.

## SEC filing metadata
- accession: 0001193125-26-099424
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312526099424/0001193125-26-099424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312526099424/prld-20260310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-099424
- JSON: https://secwatch.observer/filing/0001193125-26-099424.json
- Plain text: https://secwatch.observer/filing/0001193125-26-099424.txt

## Key facts
- Earnings Releases
  Prelude Therapeutics Inc reported financial results for the full year ended December 31, 2025.
  - Period: the full year ended December 31, 2025
  - Result: reported results
  source text: Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the full year ended December 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000119312526099424/0001193125-26-099424-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.